XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue- Incyte Corporation (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended 90 Months Ended
Aug. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2017
USD ($)
performanceObligation
Dec. 31, 2018
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jul. 31, 2022
USD ($)
Collaboration And Other Agreements [Line Items]                          
Total revenues       $ 22,241,000 $ 10,797,000 $ 35,434,000 $ 19,901,000            
Deferred revenue, current       7,872,000   7,872,000   $ 16,319,000     $ 7,872,000    
Deferred revenue, net of current portion       55,745,000   55,745,000   55,503,000     55,745,000    
Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment                 $ 150,000,000        
Potential commercial milestone payments under agreement                 330,000,000        
Potential development and regulatory milestone payments under agreement                 210,000,000        
Development and regulatory milestones recognized $ 100,000,000             100,000,000     215,000,000    
Collaborative agreement transaction price                 $ 154,000,000        
Variable consideration recognized                   $ 4,000,000      
Number of performance obligations | performanceObligation                 2        
Gilead | Gilead First Research Program                          
Collaboration And Other Agreements [Line Items]                          
Total revenues   $ 3,300,000   5,600,000 1,300,000 11,000,000 2,000,000            
Deferred revenue, current       0   0   11,000,000     0    
Minimum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)                 15.00%        
Maximum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)                 24.00%        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Total revenues       1,300,000 100,000 1,800,000 300,000   $ 150,000,000        
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                          
Collaboration And Other Agreements [Line Items]                          
Total revenues       0 400,000 400,000 800,000            
RevenuesFromCMOAgreementsMember | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment     $ 10,000,000                    
Annual Fixed Payments     14,400,000                    
Total revenues       13,300,000 $ 2,100,000 18,300,000 $ 4,300,000            
Deferred revenue, current       $ 0   $ 0   $ 3,400,000     $ 0    
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Annual Fixed Payments     $ 41,700,000                    
Additional Payments                       $ 13,500,000 $ 5,100,000
Manufacturing Services | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Extension term                         1 year
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                          
Collaboration And Other Agreements [Line Items]                          
Revenue, remaining performance obligation, expected timing of satisfaction     3 years